INHANCE Consortium

摘要 每年有近60万例头颈癌(HNC)被诊断出来，32.5万人因此死亡 到世界上的HNC。HNC是一组发生在口腔、口咽、下咽和口腔的恶性肿瘤。 喉咙。由于烟草和酒精的共同风险因素，他们被一起研究，但他们各自都有 具有明显的流行病学和临床特征。例如，人类乳头瘤病毒(HPV)感染就是一个很大的风险 这是口咽癌特有的因素，也是口咽癌发病率上升的原因。《国际邮报》 头颈部癌症流行病学(INHANCE；http://www.inhance.utah.edu)联合会，成立于 2004年，是一个非常富有成效的联盟，在HNC研究方面有着良好的合作记录。虽然 在确定生活方式风险因素和基因、挑战方面，HNC研究取得了很大进展 包括与患者更直接相关的子站点分组和研究结果。我们的会议将 汇聚世界HNC流行病学专家，目标如下：1)建立一个主管和 宫颈癌亚组共识小组，2)讨论以人群为基础的头部的潜力 和宫颈癌患者提供患者和临床医生需要的信息以及头部和 中低收入国家(LMIC)的宫颈癌研究。HNC子站点分组有 经过几十年的进化，但并不是该领域的所有研究人员都采用了新的分组。各种癌症 到目前为止，登记的报告包括鼻咽癌和唾液腺癌，如口腔癌和 咽癌。将这些不同的疾病组合在一起是不合适的，并会造成癌症的混淆 趋势和风险因素。协商一致小组将起草一份文件，建议未来的子网站分组 学习。此外，尽管INHANCE财团传统上专注于确定风险因素， 为HNC患者提供基本信息的研究是流行病学家可以贡献的一个领域 值得注意的是强有力的基于人口的研究。目前的NCCN生存指南中写道： 癌症及其治疗的各种影响的流行程度很难量化，因为很少有研究 以纵向方式解决了这些问题。总体而言，癌症幸存者的晚期效应的流行率 据信随着时间的推移而增加，可能是因为抗癌干预变得更加复杂 和紧张的…“。我们将讨论HNC未来的潜在研究、合作和优先假设 患者队列，重点关注癌症幸存者的晚期效应。HNC流行病学家潜力巨大 为HNC幸存者的临床指南，如NCCN，以及可能的治疗决策做出贡献 在精心设计的流行病学研究中，治疗引起的迟发效应得到了适当的表征。 最后，大多数头颈部癌症病例都是在LMICs被诊断出来的，但大多数研究都是 在高收入国家进行。我们将讨论头颈部研究的优先领域。 癌症对LMIC的最大影响是降低这种疾病在LMIC中的发病率和死亡率。

ABSTRACT Each year almost 600,000 head and neck cancers (HNC) cases are diagnosed and 325,000 deaths occur due to HNC in the world. HNC are a group of malignant cancers in the oral cavity, oropharynx, hypopharynx and larynx. They are studied together due to their shared risk factors of tobacco and alcohol, but they each have distinct epidemiologic and clinical features. For instance, human papillomavirus (HPV) infection is a strong risk factor specifically for oropharyngeal cancers and is contributing to it’s increasing incidence. The International Head and Neck Cancer Epidemiology (INHANCE; http://www.inhance.utah.edu) Consortium, established in 2004, is a very productive consortium with an excellent record of collaboration on HNC research. Although great advances have been made in HNC research to identify lifestyle risk factors and genes, challenges include subsite groupings and research results that are more directly relevant to patients. Our meeting will bring together the world’s experts on HNC epidemiology with the following aims: 1) to establish a Head and Neck Cancer Subsite Grouping Consensus Panel, 2) to discuss the potential of population-based head and neck cancer patient cohorts on providing information that patients and clinicians need and 3) head and neck cancer research in low and middle income countries (LMIC). The HNC subsite groupings have evolved over the decades, but not all researchers in the field have adopted the new groupings. Various cancer registry reports to this day include nasopharyngeal cancers and salivary gland cancers as ‘oral cavity and pharynx’ cancers. Combining such distinct diseases together is inappropriate and creates confusion for cancer trends and risk factors. The Consensus Panel will draft a paper to propose the subsite groupings for future studies. Additionally, although the INHANCE consortium has traditionally focused on identifying risk factors, studies that provide basic information for HNC patients is an area that epidemiologists can contribute to significantly with robust population-based studies. The current NCCN survivorship guideline states “The exact prevalence of various effects of cancer and its treatment are hard to quantify, because few studies have addressed these issues in a longitudinal fashion. In general, the prevalence of late effects in cancer survivors in believed to have increased over time, likely because anticancer interventions have become more complex and intense …”. We will discuss potential future studies, collaborations, and priority hypotheses for HNC patient cohorts with a focus on late effects among cancer survivors. HNC epidemiologists have great potential to contribute to clinical guidelines such as the NCCN for HNC survivors and possibly for treatment decisions when late effects due to treatments are characterized appropriately in well-designed epidemiologic studies. Finally, the majority of head and neck cancer cases are diagnosed in LMICs, but the majority of research is conducted in high income countries. We will discuss the high priority areas of research for head and neck cancer in LMIC for maximal impact to reduce the morbidity and mortality of this disease in LMICs.